We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich

We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”.

💎 ABOUT THE SPEAKER

Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer vaccine company, helped see through a multi-million dollar deal of over €20M, and much more.

🔗 LINKS MENTIONED

- Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167038

📜 TRANSCRIPT

Read the full transcript here:

🫶 FOLLOW US

- Newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X: https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS

[00:00:00] Intro

[00:01:47] Novo Nordisk deal

[00:10:19] Results from heart disease phase1

[00:19:55] MicroRNA

[00:26:42] The history of Cardior

[00:41:49] Working with Centerview

[00:45:17] Frau Biotech

[00:53:57] Thanks for listening

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKER I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. 🔗 LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocore’s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow. 💎 ABOUT THE SPEAKER Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. I interviewed him back in 2018 when he sold the company. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/edwin-moses-biotech-platforms/

🔗 LINKS MENTIONED

• Sanofi to acquire Ablynx for €3.9 Billion - https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-29-07-19-03-1313306

Edwin Moses on stage in 2018 - https://www.youtube.com/watch?v=nWkd99rxVhc&t=802s&pp=ygUVZWR3aW4gbW9zZXMgbGFiaW90ZWNo 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS